**Core Concept**
The question is testing the knowledge of the cardiovascular safety profile of Selective Serotonin Reuptake Inhibitors (SSRIs), a class of antidepressants commonly used to treat depression and anxiety disorders. The correct answer will be the SSRI that is known to have a favorable cardiovascular safety profile.

**Why the Correct Answer is Right**
Among the SSRIs, **Citalopram** is known to have a relatively favorable cardiovascular safety profile. This is because it has a lower risk of QT interval prolongation compared to other SSRIs, such as **A. Escitalopram** (which has a higher risk of QT interval prolongation) and **D. Paroxetine** (which has a higher risk of QT interval prolongation and increased risk of bleeding). **B. Sertraline** is also not known for its particularly favorable cardiovascular safety profile.

**Why Each Wrong Option is Incorrect**
* **Option A: Escitalopram** has a higher risk of QT interval prolongation, which can increase the risk of serious cardiac arrhythmias.
* **Option B: Sertraline** has a higher risk of QT interval prolongation and increased risk of bleeding.
* **Option D: Paroxetine** has a higher risk of QT interval prolongation and increased risk of bleeding.

**Clinical Pearl / High-Yield Fact**
When prescribing SSRIs, it's essential to consider the patient's cardiovascular risk factors and monitor for signs of QT interval prolongation, such as palpitations, dizziness, or syncope.

**Correct Answer: C. Citalopram**